Search

everythinglearnresearchcommunity

for

Search:↓

Combining topical dutasteride with microneedling is more effective for hair growth than microneedling alone.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Antiandrogens don't help with COVID-19 and aren't recommended.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.

A new gene, JMJD1C, may affect testosterone levels in men.

DNA variants can predict male pattern baldness, with higher risk scores increasing baldness likelihood.

Hair loss increases with age; alcohol raises risk, more female partners lowers it.

Longer CAG and GGN repeats increase alopecia risk, but no significant link to post-finasteride syndrome found.

Women with AGA have higher lipid levels, increasing heart disease risk.

AGA progression involves increased lipid synthesis, electron transport, and hair follicle miniaturization.

No definitive link between finasteride and male breast cancer, but further research is needed.

Early hair loss may be linked to metabolic syndrome.

Researchers developed reliable models to predict how well certain compounds bind to androgen receptors, emphasizing the importance of atomic electronegativity.

Higher leptin levels link to hair loss.

The triterpenoids from Ganoderma lucidum can block testosterone effects and may help treat enlarged prostate.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Male cancer patients have a higher risk of severe illness and death from COVID-19 than female patients.

The protein ARA70/ELE1 is involved in male pattern baldness, and lower levels of its short form may lead to hair thinning.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Early hair loss links to metabolic issues in young Indian men.

Women with alopecia may have a higher chance of getting thyroid cancer.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Dermatologists should carefully manage hair loss in cancer patients to improve their quality of life.

Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.

PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

FOXC1 boosts SFRP1 in hair loss, suggesting new treatments.

ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.